100 Participants Needed

Proton Radiation Therapy for Prostate Cancer

(PR11 Trial)

IC
Overseen ByIntake Coordinator
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: University of Florida
Must be taking: Androgen deprivation therapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does exclude people who are currently taking certain blood thinners like warfarin, heparin, and others. It's best to discuss your specific medications with the trial team.

What data supports the effectiveness of the treatment HR-A, HR-B in the clinical trial for Proton Radiation Therapy for Prostate Cancer?

Research shows that proton therapy, a type of radiation treatment, has positive outcomes for prostate cancer, with studies reporting good results over 5 to 7 years. This suggests that similar treatments like HR-A and HR-B could also be effective.12345

Is proton radiation therapy safe for prostate cancer patients?

Research shows that proton radiation therapy for prostate cancer is generally safe, with studies reporting on early side effects and quality of life. Patients have experienced some gastrointestinal issues, but overall, the treatment is considered feasible and manageable.678910

How does proton radiation therapy differ from other treatments for prostate cancer?

Proton radiation therapy is unique because it uses a proton beam that can deliver high doses of radiation directly to the prostate tumor with minimal impact on surrounding healthy tissues, thanks to a property called the Bragg peak. This allows for potentially higher doses of radiation compared to traditional X-ray therapies, which may lead to fewer side effects.26111213

What is the purpose of this trial?

The purpose of this research study is to determine if dose-escalated proton radiation therapy is a good way to treat high-risk prostate cancer. The study features hypofractionation and a simultaneous integrated boost to the magnetic resonance imaging (MRI) identified intraprostatic tumor (IPT) as a method of dose-escalating radiation therapy. The study will include patients with high-risk prostate cancer who are at the highest risk for recurrence. Radiation therapy will be delivered over the course of 8-9 weeks. Additionally, androgen deprivation therapy (ADT) will be started 8-10 weeks prior to starting radiation and continued for a total of 18 months if the patient decides to receive ADT.

Research Team

CM

Curtis M Bryant, MD, MPH

Principal Investigator

University of Florida Health Proton Therapy Institute

Eligibility Criteria

Men over 18 with high-risk prostate cancer, who haven't had previous local treatments or pelvic radiation. They must have a visible tumor on MRI, no distant metastasis or positive lymph nodes, and be able to start treatment within 16 weeks of signing up. Participants should not have severe heart failure, end stage renal disease, inflammatory bowel diseases affecting the rectum, or recent major intrapelvic surgery.

Inclusion Criteria

Hemoglobin must be ≥ 10 g/ml within 4 months prior to registration
I have been mostly active and able to carry out all pre-disease activities without restriction in the last 4 months.
If patient has child-producing potential, they must be willing to use medically acceptable contraception during treatment and must be advised to use it for at least 1 year thereafter. This is not applicable if the patient is not sexually active or has had a vasectomy
See 7 more

Exclusion Criteria

My prostate size changed by more than 25% since my last MRI, and I need another MRI.
Patients with positive nodes on cross-sectional imaging
I have an active inflammatory bowel condition affecting my rectum.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Androgen Deprivation Therapy (ADT)

ADT is started 8-10 weeks prior to radiation and continued for a total of 18 months

18 months

Radiation Therapy

Dose-escalated proton radiation therapy delivered over 8-9 weeks with a simultaneous integrated boost to the MRI identified intraprostatic tumor

8-9 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of biochemical failure, local recurrence, and overall survival

5 years

Treatment Details

Interventions

  • HR-A
  • HR-B
Trial Overview The trial is testing if dose-escalated proton radiation therapy can better treat high-risk prostate cancer. It involves hypofractionation and an integrated boost targeting the tumor identified by MRI over 8-9 weeks. Androgen deprivation therapy may also be used for 18 months.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: HR-B (High-risk B)Experimental Treatment1 Intervention
* Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent. * Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent. * Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent. * Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent.
Group II: HR-A (High-risk A)Experimental Treatment1 Intervention
* Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent. * Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials
1,428
Recruited
987,000+

Findings from Research

In a study of 215 prostate cancer patients treated with image-guided accelerated hypofractionated proton therapy, the 5-year rates of freedom from disease progression were very high, at 95.9% overall, indicating strong efficacy of this treatment approach.
The treatment resulted in minimal severe toxicities, with only 0.5% experiencing significant gastrointestinal issues and 1.7% facing severe urologic toxicities, suggesting that this therapy is safe for selected patients.
Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer.Henderson, RH., Bryant, C., Hoppe, BS., et al.[2018]
In a study of 211 prostate cancer patients treated with image-guided proton therapy, early outcomes showed high efficacy with only 1.9% experiencing Grade 3 genitourinary (GU) symptoms and less than 0.5% experiencing Grade 3 gastrointestinal (GI) toxicities after a minimum follow-up of 2 years.
The need for pretreatment GU symptom management was linked to higher rates of posttreatment GU symptoms, indicating that managing symptoms before therapy may help reduce complications.
Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.Mendenhall, NP., Li, Z., Hoppe, BS., et al.[2022]
In a study of 582 prostate cancer patients treated with moderately accelerated hypofractionated proton therapy (AHPT), the 5- and 7-year rates of freedom from biochemical progression were very high, at 96.8% and 95.2% overall, indicating strong long-term efficacy of this treatment.
The treatment was associated with minimal toxicities, with low rates of grade 2 gastrointestinal (9.9% at 5 years) and grade 3 genitourinary (1.3% at 5 years) side effects, and no severe toxicities (grade ≥4) reported, suggesting a favorable safety profile.
Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer.Henderson, RH., Bryant, CM., Nichols, RC., et al.[2022]

References

A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. [2020]
Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. [2018]
Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. [2022]
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. [2018]
Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer. [2022]
Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial. [2023]
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. [2019]
Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. [2022]
Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Clinical controversies: proton therapy for prostate cancer. [2021]
Proton radiation for localized prostate cancer. [2021]
13.United Statespubmed.ncbi.nlm.nih.gov
Protons or megavoltage X-rays as boost therapy for patients irradiated for localized prostatic carcinoma. An early phase I/II comparison. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security